| Blood glucose | - Postprandial – Target <140 mg/dL (7.8 mmol/L) at 1 to 2 hours.
- Fasting blood glucose – Target 70 to 90 mg/dL (3.9 to 5 mmol/L), when on basal insulin.
|
| Continuous glucose monitoring | - For screening – May be helpful if a patient has dysglycemia and indications for insulin treatment are unclear.
- For treatment – Valuable for all patients on insulin but especially for those with poor growth.
|
| Complications screening[1] | - Blood pressure measurement at all routine visits.
- Annual screening for microvascular complications, beginning 5 years after the diagnosis of CFRD:
- Dilated eye examination for retinopathy
- Urine albumin:creatinine ratio (spot specimen)
- Foot examination with testing for vibration (tuning fork) and pressure (10 g monofilament)
- Lipid profile for selected patients with risk factors for hyperlipidemia (post-transplantation, obesity, or family history of early coronary artery disease)
|
| Pulmonary function testing | - Perform every 3 months to assess lung function. Optimal therapy for CFRD tends to improve pulmonary function.
|
